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Abstract 
The physical stability of therapeutic proteins is a major concern in the development of liquid 
protein formulations. The number of degrees of freedom to tweak a given protein’s stability is 
limited to pH, ionic strength and type and concentration of excipient. There are only very few, 
mostly similar excipients currently in use, limited to the short list of substances generally 
recognized as safe for human use by the FDA. Opposed to the limited number of molecules the 
formulation scientist has at hand to stabilize a protein, there is the vastness of chemical space 
which is hypothesized to consist of 1060 compounds. Its potential to stabilize proteins has never 
been explored systematically in the context of stabilization of therapeutic proteins. Here we present 
a screening strategy to discover new excipients to further stabilize an already stable formulation 
of a therapeutic antibody. We use our data to build a predictive model to evaluate the stabilizing 
potential of small molecules. We argue that prior to worrying about the hurdles of toxicity and 
approval of novel excipient candidates, it is mandatory to assess the actual potential hidden in the 
chemical space. 
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Introduction 
Formulation of therapeutic proteins is a field of ongoing research as the proteins can degrade in 
multiple ways. The process of identifying a suitable formulation occurs typically by screening 
solution conditions that vary by pH and ionic strength3. Additionally, stabilizing substances, so 
called excipients are added. These can be categorized as for example surfactants, buffers, amino 
acids, polymers, proteins, metal ions, tonicity modifiers, sugars and polyols, salts, preservatives, 
antioxidants, chelators, antimicrobials. A recent review mentions 57 different substances2. 
Examples include polysorbates, polyethylene glycols, several sugars, several proteogenic amino 
acids or cyclodextrin4–6. The chemical space of molecules consisting of up to 30 carbon, oxygen, 
nitrogen or sulfur atom has been estimated to contain 1060 different molecules7. Taking into 
consideration that many of the aforementioned excipients are structurally very similar, the portion 
of the chemical space covered by currently employed excipients is next to nothing.  
Hurdles in introducing new excipients to formulations of therapeutic proteins are the risk of their 
toxicity and the costly and time-consuming approval process, which for an excipient is as tedious 
as for a drug. Additionally, excipients have to be chemically stable and should have a sufficient 
aqueous solubility. Therefore, industry often limits the arsenal of potential excipients during 
formulation development to the selection of excipients that the FDA generally recognizes as safe 
(GRAS list)8,9. However, there has been no systematic evaluation of possible benefits that may be 
introduced by new excipients. A better understanding of the potential to stabilize proteins hidden 
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in the chemical space could eventually provide a motivation to overcome the aforementioned 
hurdles.  
Monoclonal antibodies (mAbs) represent the most important and best-selling class of therapeutic 
proteins in recent years10. A lot of research effort has been dedicated to optimize their sequences, 
in order to guarantee that their development will not pose a risk to the outcome of any clinical 
trial11. One important strategy in sequence optimization consists in mutating aggregation prone 
regions12. When analyzing 28 therapeutic mAbs using Aggrescan3D, we found that aggregation 
prone moieties are present in the paratope for 20 of them (unpublished data)13. It seems plausible 
that sequence optimization is, among other factors, limited by the required affinity of the mAb to 
its target, often driven by hydrophobic patches in the mAb’s complementarity-determining region. 
New excipients could therefore present a way to push the boundaries of current state formulations 
even with optimized protein sequences. This is desirable to achieve for example formulations that 
are stable at room temperature, making refrigeration and freeze-drying obsolete. 
Besides their application in biopharmaceutical products, new excipients could easily be employed 
to stabilize proteins used for diagnostics or in bioprocesses, where their potential toxicity is less 
of a concern. 
To identify excipient candidates, their effect on protein stability has to be evaluated 
experimentally. In long-term stability studies, formulations are stored for numerous months or 
even years. The formation of aggregates and chemical changes in the formulation are monitored 
for example by chromatographic or microscopic methods. Due to the limited throughput and time-
constraints, this approach is not plausible for the purpose of screening a library of small molecules 
on their effect on protein stability. Instead, forced degradation studies have been developed as 
indicators of long-term protein stability. Differential scanning fluorimetry (DSF) measures 
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changes in extrinsic fluorescence upon unfolding of a protein when exposed to heat. Similarly, in 
nanoDSF the measured changes are of the intrinsic fluorescence of the protein’s tryptophan and 
tyrosine residues. The inflection point (apparent protein melting temperature, Tm) of the 
characteristic unfolding curve serves as a surrogate to measure a protein’s conformational stability. 
As extrinsic dye, SYPRO orange is one of the most common choices. The same method is also 
known as thermal shift assay in the drug discovery community, where it is used to identify new 
small molecular active compounds14. Light scattering, backscattering or optical density is often 
used simultaneously to monitor the formation of aggregates. The derived temperature of onset of 
aggregation (Tagg) is another common stability indicator. While DSF and nanoDSF are excellent 
choices regarding throughput and sample consumption, their correlation with long-time stability 
data is limited15. More recently, the ReFOLD assay has been proposed as stability indicating 
method, showing excellent correlation with long-term stability data16,17. In a first step, the protein 
is chemically denaturated by dialyzing against the formulation buffer containing Urea. 
Subsequently, the Urea is removed by dialyzing against the formulation buffer, leading to a 
refolding of the protein. During the process of Urea removal, the protein will be partially unfolded 
and not fully solubilized, making it prone to aggregate. The degree of aggregation measured for 
example by size exclusion chromatography can then be considered a surrogate for protein stability. 
As the ReFOLD assay relies on dialysis, it requires larger buffer volumes and has a lower 
throughput than for example DSF or nanoDSF measurements. 
In this work we make use of chemoinformatic methods to classify and describe small molecule 
structures for multiple purposes. Very broadly speaking, there are two approaches to classify a 
small molecule in a machine-readable way. This is either through physicochemical descriptors, 
such as for example hydrophobicity, or descriptors of structural features, such as the occurrence 
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of a functional group. Both of these classification approaches have been implemented in a lot of 
different ways for numerous purposes. An excellent overview on the topic is given for example by 
Leach et al.18. One way to define hydrophobicity as physicochemical descriptor is the 
octanol/water partition coefficient of a substance (P). Numerous ways to predict P for a given small 
molecule exist19. Structural features of small molecules are commonly represented by binary 
vectors with multiple implementations. In one approach, each element of the vector corresponds 
to a predefined structural feature or key, as for example in the Molecular Access System keys 
(MACCS) method20,21. If for example the first MACCS key is present in the small molecule, its 
vector’s first element will be set to 1. If the key is absent, the vector element is set to 0. In the case 
of so-called hashed fingerprints such as Morgan or Daylight fingerprints, the vector’s elements do 
not directly correspond to a specific structural element. Instead they are calculated by an algorithm 
that considers connectivity or atom environment within a molecule. 
The machine-readable description of a molecule can be exploited to build models that relate the 
descriptors to experimental observables, often referred to as quantitative structure activity 
relationship (QSAR). In QSAR, each physicochemical descriptor or vector element is considered 
a variable that can be fed to a machine learning algorithm in order to predict an unknown variable 
such as for example the biological activity of a small molecule22. Another example is the use of 
SYPRO Orange based DSF measurements of a mAb to build a QSAR model that predicts the 
effect of 79 osmolytes on the mAbs stability. The substances were similar to currently employed 
excipients, such as amino acids, methylamines and polyols 23.  
Here we present an approach to identify small molecules that stabilize a mAb, starting from the 
selection of a suitable library by a chemoinformatic approach that focuses on compound diversity 
and hydrophobicity. We then screen the selected library by DSF and nanoDSF combined with 
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backscattering to identify hit substances based on Tm and Tagg. After a hit expansion with analog 
substances we use the ReFOLD assay to identify excipient candidates and finally build a predictive 
QSAR model by using multiple regression. 
Results 
Library selection 
Since there are only very few excipients commonly used in protein formulations, it is not possible 
to apply any general rules to the library design such as for example Lipinski’s rule of five known 
from drug discovery11. We therefore opted to screen a library covering as much of the chemical 
space as possible. It was therefore required to be highly diverse. We quantified a library’s diversity 
by considering its median pairwise Tanimoto coefficients calculated based on Morgan and RDkit 
daylight-like fingerprints. Limited lipophilicity was the only additional criterion imposed to assure 
sufficient solubilities. To keep time and cost of the first screening step reasonable, the library’s 
size should be in the range of 1000-2000 compounds. Furthermore, we checked for the presence 
of pan-assay interfering substances (PAINS) and reducing sugars, which, however, were found to 
be very sparse in all cases, and thus not critical to decision making. The cost of the libraries was 
another key aspect since prices ranged from approx. 2000 € to 170000 €.  
In total, we compared 19 different commercially available libraries from different vendors. Their 
median SlogP values ranged from approximately 1.5 to 3.5. Median similarities depended strongly 
on the type of descriptor used. The “Chemspace PPI Modulators library” (D) was found to be the 
least diverse and most hydrophobic library and fragment libraries from Enamine and Compound 
Cloud to be the most diverse and hydrophilic. Being the most cost-effective, we selected the 
“Enamine Golden Fragment Library” (Q). However, other selections would have also been 
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plausible. The library consists of mostly aromatic scaffolds (Figure S 3), does not contain any 
reducing sugars and less than 1% of PAINS. 
Library screen 
The change in thermal stability of protein induced by a small molecule, typically referred to as 
thermal shift, is commonly employed in drug discovery to identify active compounds. It is also an 
indicator of the stability of a protein in a given formulation. A shift towards higher temperature 
corresponds to a binding/interaction of the small molecule with the protein’s native state24,25. 
Based on the same assumption that a stabilizing excipient also binds to the native state of the 
protein (or destabilizes the unfolded state), a positive shift is considered by us an indicator of a 
stabilizing protein formulation. By measuring the thermal shift of a therapeutic antibody (LMU-
01) induced by all 1800 substances from the Enamine GFL we combined the rational from drug 
discovery and protein formulation screening (Figure 2). The stability of a given protein can be 
optimized easily and at low cost by adjusting pH and ionic strength. The use of excipients is 
therefore only meaningful, once these basic formulation properties have been optimized. We 
therefore selected an already optimized starting formulation for our excipient screen. Since our 
screening methods rely on temperature gradients, we limited the buffer choice to phosphate, as its 
pH has a low susceptibility to temperature15. The assay was performed at low protein 
concentrations to ensure an excess of small molecule, whose limited availability in the library 
during the screen was considered a bottleneck.  
The screen was performed in the following way: first all 1800 substances were tested by DSF and 
backscattering measurements. Hits from any of the measurements were then further evaluated by 
the ReFold method.  
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For the DSF screen, Substances exceeding the threshold of 3 °C for ΔTm2 were considered for 
additional orthogonal screening. As 41 substances would exceed our capacities to measure in the 
ReFold assay, they were evaluated in an additional backscattering measurement by their effect on 
the onset of aggregation temperature Tagg compared to an excipient free control. Three substances 
exhibited a Tagg higher than that of all three control measurements (Figure 3). These were then 
considered for the refolding study.  
The backscattering screen yielded 10 substances with a Tagg higher than that of the control. Of 
these, only one substance, 380610-68-4, was affordable in price and selected for the ReFold study. 
Three substances from the DSF screen and one substance from the backscattering screen and six 
analog substances were purchased for further evaluation in the ReFold assay (Table 1). 
ReFold 
The ReFold assay has previously been shown to accurately predict the long-term stability of 
various therapeutic mAb formulations. It is strictly orthogonal to the fluorescence-, light 
scattering- and temperature stress-based methods employed in the first selection steps. It is 
therefore highly suitable to evaluate the candidate excipients and eliminate false positive results. 
Out of the 10 candidates (4 hits and 6 analogs) selected, we identified five that would increase the 
relative monomer area compared to the excipient free formulations and formulations containing 
the standard excipients sucrose, L-arginine or D(+)-trehalose. The substance 1803599-38-3 turned 
out to be a false positive (Figure 4).  
Four out of the five stabilizing compounds show a clear interaction with the protein upon unfolding 
as can be seen in nanoDSF measurements (Figure 5). Control experiments show that the change 
in curve shapes are not caused by a temperature dependence of the small molecules’ fluorescence 
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signals (Figure S 1). A change in curve shape was also observed for compound 127988-21-0 in 
the initial DSF screen, but not for compound 380610-68-4 (Figure S 2), for the other substances 
no DSF data is available since they are analogs purchased after the initial library screen. 
QSAR 
The data from the ReFold assay was used to evaluate the effect of structural features of a small 
molecule on the relative monomer area by constructing a model through multiple regression. The 
model is built from 8 MACCS keys and achieves an R2 of 0.49 and RMSE of 2.13 (Figure 6). We 
found that structures containing MACCS keys 89 and 157 would lead to a decreased relative 
monomer area, while substances containing MACCS keys 91, 100, 117, 131, 132, 150 would 
increase the relative monomer area of the ReFold assay (Table 2). 
Discussion 
The two criteria regarding library selection, diversity and hydrophilicity, allowed us to select a 
compound library covering a broad part of chemical space with substances with a reasonable 
solubility in aqueous formulations. The libraries considered in our analysis were all from 
commercial vendors and designed for the purpose of drug discovery. The selected “Golden 
Fragment Library” has been already used in a thermal shift screen to identify to identify inhibitors 
of bromodomain-containing protein 426. The advantages of selecting a commercial library are that 
the cost per amount of substance is lower and that the libraries are curated and tested. Ideally this 
avoids pitfalls like PAINS, reactive or unstable substances. Substances from commercial libraries 
are furthermore provided pre-dissolved in well plates, allowing for an easy transfer with standard 
multi-pipettes. Typically, the substances found in commercial libraries can also be obtained 
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individually at a reasonable cost, together with analogs, which makes following up on any hit 
molecules straightforward. 
As typically observed for mAbs, the temperature dependent fluorescence signal of LMU-01 shows 
two transitions (Tm1 and Tm2). From measurements of backscattering of light as an indicator of 
aggregate formation, the second transition, corresponding to the unfolding of the Fab fragment, 
has been identified to induce particle formation. The point density from the DSF measurements is 
only 1/K, which results in a considerable level of noise. We therefore selected candidates for 
further exploration based on thermal shifts of Tm2 above 3 °C. 
The selected compounds were then evaluated by simultaneous nanoDSF and backscattering 
measurements, with backscattering being a truly complementary detection method to DSF to 
evaluate actual particle formation. The low working volumes did not allow for pH adjustment at 
this stage, inevitably leading to false positive and negative measurements, since shifts to lower pH 
typically increase the electrostatic repulsion among mAb molecules with pI values between 7-927. 
Selecting a higher buffer concentration may be an approach to mitigate the risk of pH shifts, 
however, at the cost of increased ionic strength, altering the proteins reference stability profile. 
The presence of DMSO as standard solvent known from drug discovery screens was an additional 
source of error which we considered inevitable. For the last step of the screening we adjusted pH 
and worked in DMSO free conditions, leading to reduced solubilities of the candidate compounds 
and an altered protein stability profile. Additional false positive results could therefore be 
identified by the ReFold assay in the last screening step. 
In order to screen the library for its effect on protein stability, we considered three different 
analytical methods. DSF (in the presence of SYPRO Orange), nanoDSF/backscattering and SLS 
(data not shown). By using two fluorescence-based methods, two different excitation and three 
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emission wavelengths are covered. If a compound’s fluorescence happens to interfere in one of the 
assays, this ensured that it would not interfere in the other one. DSF measurements could be 
performed at a high throughput due to its well plate-based format. The use of SYPRO Orange as 
extrinsic fluorescent dye allowed for a very sensitive monitoring of mAb unfolding based on the 
exposure of hydrophobic regions, buried inside the core of the protein’s native conformation. 
Consequently, the presence of extrinsic dye may also interfere in the interaction between the tested, 
partially hydrophobic substances and the protein. Furthermore, the low resolution of the 
measurement introduced a significant amount of noise. Another drawback was the lack of 
dedicated software to analyze the data, requiring the generation of our own script. In contrast, data 
from nanoDSF and simultaneous backscattering measurements had a vastly higher resolution than 
our DSF measurements and the provided software allowed for a straightforward way to handle the 
large amount of data. Since the capillary based system makes sampling loading a time-consuming 
drawback, a capillary-chip-based version of the instrument equipped with an automated sample 
loading device was used in this study. SLS/DLS measurements provide a sensitive way to detect 
the formation of protein aggregates in a well-plate format. Here, in order to prevent evaporation 
of the sample either silicon oil or adhesive films have to be used. Due to the hydrophobic nature 
of some of our substances, only the use of films was plausible for our case. While the method 
requires very low sample volumes, DLS measurement require long measurement times and are 
therefore a limitation to throughput. We therefore tested the use of scattering intensity (SLS) as a 
fast and sensitive readout to detect aggregate formation in isothermal conditions. Whereas this 
experiment would have presented a complementary approach to the DSF and nanoDSF 
experiments, it did not turn out to be sufficiently robust. Possible reasons could be the formation 
of air bubbles during the measurement and detachment of the adhesive film. Further optimization 
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of the assay in terms of adhesive film selection and adhesion process was not feasible in the 
timeframe of this work. One could also consider the method as an intermediate screening step, 
where the number of candidates is already narrowed down and replicate measurements can be 
performed in a reasonable time frame. 
After candidate selection through DSF, nanoDSF and backscattering measurements, we purchased 
the hit substances together with analog compounds. The use of analogs provides a way to identify 
the functional groups responsible for the stabilizing effect and provides a mean to build a robust 
hypothesis.  
The recent development of the ReFold assay presents a straightforward, orthogonal way to 
evaluate the hits. While its throughput is considerably lower and its buffer consumption drastically 
higher than that of the other discussed methods, it requires only a minimum amount of handling, 
is highly parallelizable and relies on methods established in any protein analytics lab.  
We observe that the candidates that positively affect the relative monomer area also change the 
nanoDSF curve shape. The altered shape of the nanoDSF curves could indicate an interaction 
between the stabilizers and the (partially) unfolded species or a change in the unfolding 
mechanism, a bias that is not observed with the ReFold assay. A change in the nanoDSF curve 
shape could be considered an alternative principle for the selection of excipient candidates from 
nanoDSF screens. 
Predicting the effect of a small molecule on protein stability would be highly desirable to facilitate 
the discovery of new excipients. Through multiple regression, a model was constructed from the 
ReFold data using MACCS keys as input features to predict the effect of a substance on the assay. 
Even though it was cross validated by the leave-one-out method, its predictive power, is of course 
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limited to the design space. Nevertheless, it can be considered a starting point for more 
sophisticated models for novel stabilizing substances, as already known from drug discovery. 
More, high quality input data will enable the construction of more general models. While we also 
considered the DSF and nanoDSF screening data for model generation, we found that the signal 
to noise ratio was not sufficient to construct meaningful models. Algorithms other than multiple 
regression were tested but led to overfitting, meaning that they would also fit to the noise in the 
data. 
In this work, we purposely left out toxicity as a factor in excipient selection, but instead we 
considered it the main purpose to explore the vast potential of chemical space for protein 
stabilization. As known from drug discovery, toxicity adds another degree of complexity to the 
endeavor of identifying new substances. We suggest that this factor should be accounted for in the 
candidate optimization stage by eliminating any entities responsible for toxicity from the 
structure28. Additional factors to be considered in the optimization stage are solubility, metabolism 
and the stability of the candidate substance itself. Compatibility with buffers other than phosphate 
is an additional aspect to be taken into consideration. To fully assess the effect of an excipient on 
protein stability, long term stability and additional forced degradation studies paired with analytics 
covering all aspects of protein stability are necessary. 
Conclusion 
In order to assess the potential of substances hidden in the chemical space beyond the GRAS list 
to stabilize a protein, we rationally selected a compound library by its lipophilicity and diversity. 
We screened the library to select stabilizing candidate substances for a mAb using two different, 
complementary, standard stability indicating methods. Both DSF and nanoDSF resulted in 
different hits. Subsequently, the hit substances and analogs thereof were evaluated by the ReFOLD 
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assay, based on chemical denaturation and thus using a different physicochemical principle than 
the thermal screenings. This led to the identification of multiple substances outperforming standard 
excipients and the excipient free formulation. The candidate excipients can be developed and 
investigated further, for example in long-term stability studies and additional forced degradation 
studies. The stability of the excipient candidates themselves has to be tested as well as their 
toxicity. They could also be further optimized by structural modifications. The data was also used 
to generate a MACCS keys-based model that can predict a substance’s effect on the ReFold assay. 
The model can be used to rapidly evaluate a novel substances effect and help to identify additional 
compounds for further studies. Combining high-throughput screening of the chemical space with 
QSAR modeling enables therefore the generation of formulations with novel excipients that 
outperform those containing established GRAS list excipients. 
Methods 
Library selection 
In order to select an appropriate compound library for screening, several commercially available 
libraries were analyzed. A KNIME workflow was set up using RDkit nodes to desalt the structure 
files, calculate SlogP values as a measure of solubility and a similarity matrix by querying 
individual entries from a library against their entire library (Figure S-1). The median values for 
each property was calculated using NumPy (version 1.16.2) and plotted using Matplotlib (version 
3.0.3). 
Sample preparation 
The Enamine Golden Fragment Library was shipped in 29x 96 well plates containing stock 20 µl 
of 50 mM small molecule dissolved dimethyl sulfoxide (DMSO, Sigma-Aldrich). 250 µM stock 
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solutions of small molecules were prepared in 96 well plates (Greiner Bio-One GmbH) with 50 
mM sodium phosphate buffer at pH 6.0 (di-Sodium hydrogen phosphate dihydrate: VWR 
Chemicals, Sodium di-hydrogenphosphate dihydrate: Grüssing GmbH).  
Differential scanning fluorimetry 
LMU-01 solutions containing SYPRO orange were prepared by adding 2 µl of SYPRO Orange 
stock solution to 5 ml 1 mg/ml LMU-01 stock solution. The solution was prepared daily. The 
apparent protein melting temperature (Tm1 and Tm2) was measured with the a qTower 2.2 (Analytik 
Jena) in 96 well plates (). Final working concentrations were 0.5 mg/ml LMU-01, 1:5000 SYPRO 
orange, 125 µM ligand, 0.25% DMSO in 50 mM sodium phosphate buffer at pH 6.0. The data was 
analyzed by calculating the unfloding curves’ first derivative by using a Savitzky-Golay filter as 
implemented in the SciPy library29. The first derivative curve was fitted to a skewed gaussian by 
using the LMFIT module for Python30. 
Backreflection library screen 
Tagg, were measured with the Prometheus NT.Plex, equipped with backreflection optics, in 
standard capillary chips (NanoTemper). Final working concentrations were 0.5 mg/ml LMU-01, 
125 µM ligand, 0.25% DMSO in 50 mM sodium phosphate buffer at pH 6.0. Automated sample 
loading into capillary chips was performed with an NT.Robotic Autosampler (NanoTemper). 
nanoDSF hit confirmation 
Tagg, Tm1 and Tm2 were measured with the Prometheus NT.48, equipped with backreflection optics, 
in standard capillaries (Nano Temper). Final working concentrations were 0.5 mg/ml LMU-01, 
2 mM ligand, 4% DMSO in 50 mM sodium phosphate buffer at pH 6.0. 
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ReFold assay16 
The refolding buffer was prepared by adding a stock solution of 50 mM sodium phosphate buffer 
at pH 6.0 to excipient candidate substances to yield 5 mM solutions thereof. In cases where the 
solubility limit was exceeded, the saturated solution was used. The same procedure was used for 
the unfolding buffer which contained additional 10 M of urea. pH values were adjusted to the 
excipient free reference buffer. The resulting buffers were centrifuged at 15000 rpm. Protein 
solutions were prepared by spiking 3 µl of LMU-01 stock solution to 237 µl of refolding buffer, 
yielding a protein concentration of 1 mg/ml. Duplicates of 100 µl of protein sample were 
transferred into micro-dialysis tubes with a 3.5 kDa cutoff. Dialysis was performed at room 
temperature and unfolding buffer was exchanged after 3 h and 7 h. Refolding commenced after 24 
hs with buffer exchanges after 3 h and 7 h. 
QSAR 
MACCS keys fingerprints of the substances tested in the ReFold assay were built using the Conda 
distribution of RDkit (version 02-2019). Low variance keys were eliminated. Of the remaining 
features, those with regression coefficients close to zero were removed to rule out overfitting and 
obtain a robust model using only 8 MACCS keys. Multiple regression using leave-one-out cross 
validation was performed using Scikit learn (version 0.20.3).  
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Figure 1: Comparison of commercially available libraries. Plotted is the median of the RDkit 
Tanimoto similarity vs. the median of the Morgan fingerprints Tanimoto similarity. The marker 
color indicates the SlogP value and the marker size corresponds to the size of the library. A: 
Chemspace Pre-Plated LeadLike set; B: Chemspace_Lead-Like Compounds 5000 diversity set; C: 
Chemspace Pre-Plated Fragment-like set; D: Chemspace PPI Modulators; E: Chemspace 
General Fragments; F: Chemspace Acid Fragments; G: Chemspace 3D-Shaped Fragments; H: 
Chemspace Singleton Fragments; I: Chemspace Selected Fragments; J: Chemspace Saturated 
Fragments; K: Chemspace Amine Fragments; L: Phenotypic Toolbox; M: BCCDIV14B; N: 
Tocriscreen; O: Enamine Cys focused covalent fragments; P: Enamine DSI poised fragment 
library; Q: Enamine Golden Fragment Library; R: Enamine Fluorinated Fragment Library; S: 
CompoundCloud Selcia. Size of library M: 12030 substances, library G: 337 substances. 
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Figure 2: Thermal shifts relative to control samples from DSF measurements for all 1800 
substances. Markers of the same color correspond to samples being on the same well plate. 
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Formulation Tagg [°C] 
No Excipient 78.7 78.1 78.5 
1181867-71-
9 
79.2 79.1 - 
1803599-38-
3 
79.2 79.0 - 
127988-21-0 78.9 78.9 - 
 
Figure 3: Scattering intensity from backreflection measurements measurements and derived 
onset of aggregation temperature (Tagg) for top 3 candidate substances (n=2) and reference 
sample without excipient (n=3). 
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Figure 4: Relative monomer area after ReFold assay for formulations containing the candidate 
excipients, benchmark excipients and for an excipient free reference formulation (n=2). 
 
Figure 5: First derivative of nanoDSF data for all ReFold stabilizers. All compounds except 
1181867-71-9 significantly alter the shape of the curve in the transition region (n=3). 
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Figure 6: Multiple regression model to predict the effect of a small molecule on the relative 
monomer area determined by the ReFold assay. R2=0.49, RMSE=2.13. MACCS keys used for 
the model: 89, 91, 100, 117, 131, 132, 150, 157. 






































Table 2: Visualization and regression coefficient of MACCS keys used to build a regression 
model for the ReFold assay. * represent a wildcard. Unless specified, all bond representations 
are wildcards 
MACCS key Structural feature Regression coefficient 




















any atom – non ring bond - any atom - ring 
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Figure S 1: First derivative of Temperature dependent fluorescence signal from nanoDSF 
measurements for protein free control samples. The 350 nm/330 nm fluorescence signal of the 
tested small molecules shows a neglectable temperature dependence. 
 




Figure S 2: DSF data for compounds 127988-21-0 (top left), 380610-68-4 (top right), excipient 
free control (bottom) 
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Figure S 3: Most common scaffolds in the Enamine “Golden Fragment Library” 
